Lundbeck gets U.S. approval for epilepsy drug for children

COPENHAGEN (Reuters) - Danish pharmaceutical group Lundbeck has won approval in the United States of its epilepsy drug, Sabril, to be used in children aged 10 years and older. Lundbeck said in a statement on Monday the United States Food and Drug Administration (FDA) had approved Sabril as an add-on therapy for the treatment of refractory complex partial seizures in children who have inadequately responded to several other treatments. (Reporting by Mette Fraende; editing by David Evans)



via Health News Headlines - Yahoo! News http://news.yahoo.com/lundbeck-gets-u-approval-epilepsy-drug-children-150958112--finance.html